Please login to the form below

Not currently logged in
Email:
Password:

Ariad

This page shows the latest Ariad news and features for those working in and with pharma, biotech and healthcare.

Shire warms to Takeda’s latest offer, extending deadline

Shire warms to Takeda’s latest offer, extending deadline

too large for the Japanese drugmaker to handle, particularly after it absorbed debt to fund its $5.2bn takeover of cancer company Ariad last year.

Latest news

More from news
Approximately 18 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    acquisition of Ariad Pharmaceuticals. ... Company acquisition. Rare diseases, option to R&D pipeline. 30, 000. Ariad Pharmaceuti-cals.

  • Deal Watch May 2016 Deal Watch May 2016

    With a headline value of $140m out-licensing the European rights will enable Ariad to focus on Iclusig in the US. ... 182. Ariad Pharm/ Incyte. Acquisition and licence. Ariad's European operations; $140m upfront with tiered royalties on European sales of

  • Pharma deals in August 2015 Pharma deals in August 2015

    So it was no surprise that by the end of the month Baxalta was rumoured to be countering with deal activity of its own with discussions to buy Ariad Pharmaceuticals, an

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Research collaboration, options to license. 125. †† Ariad Pharmaceuticals / Otsuka Pharmaceutical.

  • Pharma deals during February 2014 Pharma deals during February 2014

    Financial terms for these deals were not disclosed. Also, this month Merck &Co has handed back the rights to Ariad Pharmaceutical's ridaforolimus, a mTOR inhibitor in a phase III trial ... The deal was originally reported to be worth $708m and Merck had

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Hugh Cole joins Jounce Therapeutics as chief business officer Hugh Cole joins Jounce Therapeutics as chief business officer

    He has most recently served as chief business officer at Ariad Pharmaceuticals, where he led several business development transactions for the company and helped develop and implement Ariad’s new corporate ... In addition to his former role at Ariad,

  • Alacrita appoints Anna Casse as MD Alacrita appoints Anna Casse as MD

    Ariad Pharmaceuticals, where she was responsible for building the European commercial business.

  • The Medicines Company strengthens board of directors The Medicines Company strengthens board of directors

    The Medicines Company strengthens board of directors. Paris Panayiotopoulos joins from ARIAD Pharmaceuticals. ... Panayiotopoulos has held a number of previous leadership roles - most recently as president and chief executive officer and a member of the

  • Jennifer Herron appointed as chief commercial officer of ARIAD Jennifer Herron appointed as chief commercial officer of ARIAD

    Jennifer Herron appointed as chief commercial officer of ARIAD. She brings experience from Bristol-Myers Squibb and Novartis. ... Cambridge, Massachussetts-based orphan oncology company ARIAD Pharmaceuticals has appointed Jennifer Herron as its new chief

  • Ariad appoints new CEO Ariad appoints new CEO

    Ariad appoints new CEO. Paris Panayiotopoulos joins the US biotech from EMD Serono. ... Panayiotopoulos said: “ I am very pleased to be joining ARIAD at this exciting time.

More from appointments
Approximately 6 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics